Ferroptosis: A novel anti-tumor action for cisplatin

Cancer Research and Treatment

Volumn 50, Issue 2, 2018, Pages 445-460

  Guo, Jipeng ^a   Xu, Bingfei ^a   Han, Qi ^a,b   Zhou, Hongxia ^a   Xia, Yun ^a   Gong, Chongwen ^a   Dai, Xiaofang ^a   Li, Zhenyu ^a   Wu, Gang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Xianning Center Hospital   (China)

Author keywords

Cisplatin; Erastin; Ferroptosis; Glutathione; Glutathione peroxidase

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ERASTIN; FLUOROURACIL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; IRON REGULATORY FACTOR; IRON RESPONSIVE ELEMENT BINDING PROTEIN 2; PACLITAXEL; REACTIVE OXYGEN METABOLITE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; PIPERAZINE DERIVATIVE;

A-549 CELL LINE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ELECTRON MICROSCOPY; ENZYME ACTIVITY; ENZYME INACTIVATION; FERROPTOSIS; FLOW CYTOMETRY; HCT 116 CELL LINE; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PROTEIN DEPLETION; RNA INTERFERENCE; WESTERN BLOTTING; CELL DEATH; COLORECTAL TUMOR; DRUG EFFECT; FIBROSARCOMA; LUNG TUMOR; METABOLISM; NEOPLASM; NON SMALL CELL LUNG CANCER; PATHOLOGY;

A549 CELLS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DEATH; CISPLATIN; COLORECTAL NEOPLASMS; FIBROSARCOMA; GLUTATHIONE PEROXIDASE; HCT116 CELLS; HUMANS; LUNG NEOPLASMS; NEOPLASMS; PIPERAZINES;

EID: 85044925079     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2016.572     Document Type: Article

References (28)

1. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009;16:3-11.
2. Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003;3:285-96.
3. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol. 2009;7:99-109.
4. Christofferson DE, Yuan J. Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol. 2010;22:263-8.
5. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060-72.
6. Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007;447:864-8.
7. Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15:234-45.
8. Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014;10:9-17.
9. Gout PW, Buckley AR, Simms CR, Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)-cystine transporter: a new action for an old drug. Leukemia. 2001;15:1633-40.
10. Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317-31.
11. Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369-79.
12. Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Maziere JC, Chauffert B, et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer. 2013;133: 1732-42.
13. Louandre C, Marcq I, Bouhlal H, Lachaier E, Godin C, Saidak Z, et al. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Cancer Lett. 2015;356(2 Pt B):971-7.
14. Salahudeen AA, Thompson JW, Ruiz JC, Ma HW, Kinch LN, Li Q, et al. An E3 ligase possessing an iron-responsive hemerythrin domain is a regulator of iron homeostasis. Science. 2009;326:722-6.
15. Vashisht AA, Zumbrennen KB, Huang X, Powers DN, Durazo A, Sun D, et al. Control of iron homeostasis by an iron-regulated ubiquitin ligase. Science. 2009;326:718-21.
16. Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell Mol Life Sci. 2016;73:2195-209.
17. Wang X, Guo Z. The role of sulfur in platinum anticancer chemotherapy. Anticancer Agents Med Chem. 2007;7:19-34.
18. Min Y, Mao CQ, Chen S, Ma G, Wang J, Liu Y. Combating the drug resistance of cispla-tin using a platinum prodrug based delivery system. Angew Chem Int Ed Engl. 2012;51:6742-7.
19. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4:307-20.
20. Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci. 1995;20:435-9.
21. Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016;106:27-36.
22. Richon VM, Schulte N, Eastman A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res. 1987;47:2056-61.
23. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol. 2000;60:1305-13.
24. Roh JL, Kim EH, Jang HJ, Park JY, Shin D. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. Cancer Lett. 2016;381:96-103.
25. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2005;92:131-9.
26. Cengel KA, Voong KR, Chandrasekaran S, Maggiorella L, Brunner TB, Stanbridge E, et al. Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia. 2007;9:341-8.
27. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2:e17.
28. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007;13:2890-6.